Stocks fell Thursday as investors bet the Federal Reserve will hike interest rates again in October, driving bond yields to their highest levels in 19 years.

Oracle dropped 7%. The company sent a force majeure notice to the developer of the Project Jupiter campus, its data center project in New Mexico. Although Oracle doesn't plan to exit its deal as the main tenant, the company is seeking the right to hold off payments if it doesn't come online as scheduled in 2028, Bloomberg reported.

Meta Platforms rose 2.2% after the Facebook owner showed off several new pairs of smart glasses and a hand-held device allowing users to talk to its Muse artificial-intelligence agent.

BlackBerry gained 1.7%. The company reported fiscal second-quarter earnings that surpassed Wall Street's estimates. BlackBerry attributed the performance to strong growth in its car software business.

MGM Resorts International tumbled 11% after media mogul Barry Diller's People Inc. withdrew its bid for the hotel and casino operator. "There are lots of ingredients that go into a proposal of this kind on its way to completion. We didn't feel the mix was coming together in the way we had hoped," Diller said.

Darden Restaurants declined 1.5%. Higher food and labor costs dampened the company's fiscal first-quarter earnings from a year earlier. Although revenue and adjusted earnings were in line with Wall Street's estimates, Olive Garden's same-restaurant sales growth slowed in the latest quarter.

Everpure jumped 15%. The data-storage solutions company said at an analyst presentation Wednesday that revenue growth would accelerate thanks to more hyperscaler business opportunities and booming AI demand.

Dropbox fell 3.8%. Citi downgraded the stock to Sell from Neutral on concerns that its current valuation prematurely reflects growth in its artificial-intelligence sector that the company has yet to prove.

TD Synnex tumbled 8.5% even after the information-technology giant reported stronger-than-expected earnings for its fiscal third quarter. Investor enthusiasm was likely dampened by pre-earnings valuation concerns.

Grail advanced 3.2%. A panel of medical experts said Wednesday that the Food and Drug Administration should approve the biotech's multicancer blood test, which seems likely and could come any time in the next few months. The announcement comes after shares were halted all day for Wednesday's panel meeting.